CLINICAL TRIALS PROFILE FOR COMETRIQ
✉ Email this page to a colleague
All Clinical Trials for cometriq
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01683994 ↗ | Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2012-09-07 | Background: - Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate tumors respond to it. Docetaxel and prednisone are standard treatments for advanced prostate cancer. Researchers want to see if adding cabozantinib to these two drugs can be a safe and effective treatment for this type of cancer. Objectives: - To test the safety and effectiveness of cabozantinib with standard treatments for advanced prostate cancer. Eligibility: - Individuals at least 18 years of age who have advanced prostate cancer that has not responded to standard treatments. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will also be performed. - Participants will receive the cancer drugs over 21-day cycles of treatment. They will take docetaxel and cabozantinib on day 1 of each cycle. Each docetaxel infusion will take about 1 hour. They will also take prednisone by mouth twice each day. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the study drugs for as long as their cancer does not worsen and side effects are not too severe. |
| NCT01688999 ↗ | Cabozantinib for Advanced Urothelial Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2012-09-11 | Background: - Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate and ovarian tumors respond to it. Researchers want see if cabozantinib can be a safe and effective treatment for urothelial cancer. Objectives: - To test the safety and effectiveness of cabozantinib for advanced urothelial cancer. Eligibility: - Individuals at least 18 years of age who have advanced urothelial cancer that has not responded to standard treatments. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Tumor tissue samples will also be collected. Imaging studies will also be performed. - Participants will take cabozantinib by mouth once per day on each day of a 28-day cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the study drug for as long as their cancer does not worsen and side effects are not too severe. |
| NCT01703065 ↗ | Cabozantinib in Men With Castration-Resistant Prostate Cancer | Terminated | National Cancer Institute (NCI) | Phase 2 | 2013-06-18 | This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT01703065 ↗ | Cabozantinib in Men With Castration-Resistant Prostate Cancer | Terminated | Prostate Cancer Foundation | Phase 2 | 2013-06-18 | This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT01703065 ↗ | Cabozantinib in Men With Castration-Resistant Prostate Cancer | Terminated | University of Washington | Phase 2 | 2013-06-18 | This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT01708954 ↗ | Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2013-02-13 | This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cometriq
Condition Name
Clinical Trial Locations for cometriq
Trials by Country
Clinical Trial Progress for cometriq
Clinical Trial Phase
Clinical Trial Sponsors for cometriq
Sponsor Name
